Last reviewed · How we verify
NCT06280079: LIPCAL-ALS II
Ultra-high-caloric, Fatty Diet in ALS
NA trial testing Ultra-high-caloric fatty diet in Amyotrophic Lateral Sclerosis in 392 participants. Currently enrolling.
1 June 2027
Quick facts
| Lead sponsor | University of Ulm |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 392 |
| Start date | 1 June 2024 |
| Primary completion | 1 June 2027 |
| Estimated completion | 1 June 2027 |
| Sites | 23 locations across Germany |
Drugs / interventions tested
- Ultra-high-caloric fatty diet
- Placebo
Conditions studied
- Amyotrophic Lateral Sclerosis — all drugs for Amyotrophic Lateral Sclerosis →
Sponsor
University of Ulm
Who can join
18 and older, any sex, with Amyotrophic Lateral Sclerosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims at evaluating efficacy and tolerability of an ultra-high-caloric, fatty diet (UFD) compared to placebo in patients with amyotrophic lateral sclerosis (ALS).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Alterations of Fat and Ketone Body Metabolism in ALS and SMA-A Prospective Observational Study.
Herrmann C, Uzelac Z, Michels S, Weber A, et al · · 2025 · cited 2× · PMID 40200760 · DOI 10.1111/ene.70132
Verify or expand the search:
- PubMed search for NCT06280079
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Amyotrophic Lateral Sclerosis
Currently open trials in the same condition.
- NCT07502677 — Diagnostic Accuracy of SleepImage Technology for Detecting Respiratory Failure in Patients With Amyotrophic Lateral Scle · recruiting
- NCT07478172 — Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease · NA · recruiting
- NCT07204977 — Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS) · Phase 1 · active not recruiting
- NCT07290062 — A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants · Phase 1 · recruiting
- NCT07259980 — A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD- · recruiting
Other University of Ulm trials
Trials by the same sponsor.
- NCT07436195 — Imprinting in Metabolic Diseases - Identifying Epigenetic Mechanisms in Human Gestational Diabetes Through Cell-free DNA · recruiting
- NCT07154524 — Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) · recruiting
- NCT06877143 — Hypercaloric PEG Nutrition in ALS to Sustain Energy Homeostasis · NA · recruiting
- NCT06627348 — Hilotherapy for Prevention of Chemotherapy-induced Peripheral Polyneuropathy · NA · recruiting
- NCT06170905 — Whey Protein Pre-load and Postprandial Glycemia in Pregnancy · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06280079 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Ulm
- Last refreshed: 6 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06280079.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing